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Abstract
Background: Women with type 1 diabetes strive for optimal glycemic control before and during pregnancy to avoid
adverse obstetric and perinatal outcomes. For most women, optimal glycemic control is challenging to achieve and
maintain. The aim of this study is to determine whether the use of real-time continuous glucose monitoring (RT-CGM)
will improve glycemic control in women with type 1 diabetes who are pregnant or planning pregnancy.
Methods/design: A multi-center, open label, randomized, controlled trial of women with type 1 diabetes who are either
planning pregnancy with an HbA1c of 7.0 % to ≤10.0 % (53 to ≤ 86 mmol/mol) or are in early pregnancy (<13 weeks
6 days) with an HbA1c of 6.5 % to ≤10.0 % (48 to ≤ 86 mmol/mol). Participants will be randomized to either RT-CGM
alongside conventional intermittent home glucose monitoring (HGM), or HGM alone. Eligible women will wear a CGM
which does not display the glucose result for 6 days during the run-in phase. To be eligible for randomization, a
minimum of 4 HGM measurements per day and a minimum of 96 hours total with 24 hours overnight (11 pm-7 am) of
CGM glucose values are required. Those meeting these criteria are randomized to RT- CGM or HGM. A total of 324
women will be recruited (110 planning pregnancy, 214 pregnant). This takes into account 15 and 20 % attrition rates for
the planning pregnancy and pregnant cohorts and will detect a clinically relevant 0.5 % difference between groups at
90 % power with 5 % significance. Randomization will stratify for type of insulin treatment (pump or multiple daily
injections) and baseline HbA1c. Analyses will be performed according to intention to treat. The primary outcome is the
change in glycemic control as measured by HbA1c from baseline to 24 weeks or conception in women planning
pregnancy, and from baseline to 34 weeks gestation during pregnancy. Secondary outcomes include maternal
hypoglycemia, CGM time in, above and below target (3.5–7.8 mmol/l), glucose variability measures, maternal and
neonatal outcomes.
Discussion: This will be the first international multicenter randomized controlled trial to evaluate the impact of RT- CGM
before and during pregnancy in women with type 1 diabetes.
Trial registration: ClinicalTrials.gov Identifier: NCT01788527 Registration Date: December 19, 2012.
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Background
Despite all efforts, women with type 1 diabetes in preg-
nancy continue to have increased rates of adverse preg-
nancy outcomes. Women aiming for optimal glycemic
control are at substantially increased risk of severe
hypoglycemia (episode of low blood glucose requiring
third party assistance) as well as pregnancy related
complications of gestational hypertension, preeclampsia
and delivery by caesarean section. Infants of mothers
with diabetes face increased risk of preterm delivery,
macrosomia, neonatal hypoglycemia, hyperbilirubine-
mia, respiratory distress and neonatal intensive care
unit admissions. Macrosomia itself is associated with
shoulder dystocia, birth injury, asphyxia and death. In a
study of over 1,000,000 deliveries in Ontario, Canada,
the rates of perinatal mortality and congenital anomalies
among women with pre-existing diabetes in pregnancy
were found to be approximately twice the rates of women
without diabetes [1].
Numerous studies have shown that adverse pregnancy
outcomes can be reduced with improved glycemic control.
Pre-pregnancy care has been shown to assist women to
improve glycemic control during the crucial period of or-
ganogenesis, and has been associated with reduced rates
of adverse pregnancy outcomes including major congeni-
tal malformation, stillbirth and neonatal death. However,
even motivated women who attend pre-pregnancy clinics
still struggle to achieve and maintain optimal glycemic
control [2].
CGM systems contain a subcutaneous glucose-sensing
device which measures interstitial glucose and provide
detailed information about the frequency and duration
of glucose excursions, which is either unavailable to the
user at the time of collection but available after (masked
CGM) or available at the time (RT-CGM). One study com-
paring conventional home glucose monitoring (HGM)
with masked CGM, found that CGM detected substantial
hyperglycemia (>3 hours/day) and overnight hypoglycemia
(1–4 hours) missed by conventional glucose monitoring
[3]. Another study demonstrated that pregnant women
with type 1 diabetes are still far from achieving the recom-
mended glucose control target range of 3.9–7.8 mmol/l
[4]. During the first trimester, masked CGM demon-
strated that women spent 10–12 h per day hypergly-
cemic (>7.8 mmol/L) and 2–3 h hypoglycemic
(<3.9 mmol/l). By the third trimester maternal hyper-
glycemia improved only slightly even with frequent
antenatal clinic visits.
RT- CGM use provides additional information for the
user to consider when adjusting diet, activity and insulin
doses. A systematic review in non-pregnant adults, dem-
onstrated that RT- CGM use is associated with modest
improvements in glycemic control (a mean HbA1c reduc-
tion of 0.3 %), with maximal impact (up to 1.0 % reduction
in HbA1c) in those with poor glycaemic control who use
CGM at least 6 days per week [5]. However data from two
randomized trials in pregnancy are conflicting. In a UK
trial of 71 women with type 1 and type 2 diabetes, ran-
domized to wearing a masked CGM every 4–6 weeks
compared to standard care with HGM, the use of the
CGM was associated with both reduced HbA1c (0.6 %)
and reduced risk of macrosomia (OR 0.36, 95 % CI 0.13-
0.98) [6]. A subsequent Danish trial of 154 women, ran-
domized to use RT-CGM intermittently (six days x five
times) or standard care with HGM found no difference in
glycemic control or neonatal outcomes [7]. This may have
been because women had good glycaemic control at base-
line and were not particularly compliant with RT- CGM,
with only 60 % of women using it intermittently. A system-
atic review thus concluded that more research is needed to
identify the most effective techniques of blood glucose
monitoring in pregnant women [8].
The aim of this study is to determine whether the use
of continuous RT- CGM will improve glycemic control in
women with type 1 diabetes who are a) planning preg-
nancy and b) in early in pregnancy, without substantially
increasing the rate of hypoglycemia.
Methods/design
Overall study design
CONCEPTT is a multicenter, randomized, open label,
controlled trial with an intention-to-treat analysis of two
parallel trials: one trial in women planning pregnancy, and
one in women in early pregnancy. Thirty trial centers are
located across six countries: Canada (11), UK (15), Spain
(1), Italy (1), USA (1) and Ireland (1). Women with type 1
diabetes in pregnancy who are ≤13 weeks 6 days gestation
with an HbA1c of 6.5 % to ≤10.0 % (48 to ≤86 mmol/mol),
and women with type 1 diabetes planning pregnancy with
an HbA1c of 7.0 % to ≤10.0 % (53 to ≤86 mmol/mol),
will be eligible for the run-in phase (see Fig. 1). The
run-in incorporates a 6-day period during which
women wear a masked CGM (Medtronic iPro®2 Profes-
sional CGM with Enlite2 sensor) to ensure that they
can tolerate wearing a CGM device. Women who pass
the run-in (>96 hours total with ≥24 hours overnight
[11 pm-7 am] of CGM data and at least 4 HGM
measurements per day) are eligible for randomization.
Eligible women are randomized to CGM (Medtronic
MiniMed Guardian®, Medtronic MiniMed Paradigm®
Veo™ or Medtronic MiniMed® 640G system as per
participant insulin delivery method) along with usual
HGM, or continue HGM without CGM. The primary
outcome is the change in HbA1c from baseline to
24 weeks or conception in women planning pregnancy,
and from baseline to 34 weeks gestation in women who
are pregnant.
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Primary research questions
1. Among women with type 1 diabetes who are
planning pregnancy, does the addition of RT-CGM
to HGM improve glycemic control, as measured by
change in HbA1c from randomization to 24 weeks
(or at conception), when compared to a standard
regimen of HGM without RT-CGM?
2. Among pregnant women with type 1 diabetes, does
the addition of RT-CGM to a standard regimen of
HGM improve glycemic control, as measured by
change in HbA1c from randomization in early
Fig. 1 CONCEPTT Flow Diagram
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pregnancy to 34 weeks gestation (or if pregnancy
loss, latest measurement), when compared to a
standard regimen of HGM without RT-CGM?
Eligibility criteria
To be eligible for the trial, participants must meet the
following criteria:
 Clinical diagnosis of type 1 diabetes and using daily
insulin therapy for at least one year
 Age 18–40 years
 Intensive insulin regimen involving either an insulin
pump or multiple daily injections (MDI) of insulin
 No expectation that the participant will be moving
out of the area during the next year
In addition, specific eligibility criteria apply for the pre-
pregnant and pregnant cohorts:
Pre-pregnant cohort:
 Participants are planning pregnancy and wish to
optimise glycemic control before conception
Pregnant cohort:
 Pregnancy gestation ≤13 weeks, 6 days at time of
randomization
 Live, singleton fetus
 Ultrasound (US) done to confirm gestational age,
viability and to rule out a multiple pregnancy.
Gestational age will be based on the last menstrual
period (LMP) provided (±5 days discrepancy with US dates
in the first trimester. If more than 5 days discrepancy from
US date, or LMP not known, then US dates used).
Exclusion criteria
 Type 2 diabetes
 Gestational diabetes
 Regular home user of real-time CGM in the previous
3 months
 Previous participation in the trial
 Estimated GFR <60 ml/min/1.73
 The presence of a significant medical disorder or
use of a medication such as oral glucocorticoids
that in the judgment of the investigator will affect
wearing of the sensors or completion of the
protocol.
 Inpatient psychiatric treatment in the past 6 months
 Participants using premixed fixed doses of insulin
In addition, specific exclusion criteria apply to the pre-
pregnant and pregnant cohorts:
Pre-pregnancy cohort:
 HbA1c <7.0 % (<53 mmol/mol) or >10.0 %
(>86 mmol/mol)
Pregnancy cohort:
 First HbA1c in pregnancy < 6.5 % (48 mmol/mol) or
current HbA1c > 10.0 % (86 mmol/mol)
 Known higher order pregnancies (twins, triplets, etc.).
 Known fetal anomaly.
Recruitment
Clinicians involved in the care of women with type 1
diabetes (pre-pregnant and pregnant) determine whether
a patient meets the eligibility criteria and ask if she is
interested in the trial. Interested patients are given a par-
ticipant information sheet and time to consider taking
part. Women who participate are asked to provide writ-
ten informed consent prior to commencing the run-in
period. Baseline data including diabetes history, current
diabetes management and obstetric history are obtained.
A standard physical exam (vital signs, and height and
weight measurements) is performed and the participants
complete validated questionnaires including the Blood
Glucose Monitoring System Rating Questionnaire, the
Problem Areas in Diabetes Questionnaire, the SF-12 and
the Hypoglycemia Fear Survey II. UK participants are
invited to complete a three day food diary.
Run-in
The participant wears a masked CGM for 6 days. This
provides a baseline assessment of glycemic control and
allows participants to wear the CGM before making a
decision about whether or not to continue to be ran-
domized. The participant must test using the HGM at
least 4 times per day and wear the CGM for at least
5 days, obtaining at least 96 h of glucose values and have
at least 24 h of values between 23.00–07.00 h to qualify
for randomization. The run-in CGM data are downloaded
for evaluation by an independent data coordinating center
(Jaeb Center For Health Research Inc, Tampa, Florida,
USA) and not reviewed by participants or their clinicians.
Should the first run-in be unsuccessful (due to insufficient
CGM data), a repeat CGM can be obtained.
Randomization
Participants who pass the run-in phase are randomized
to either RT-CGM in addition to their standard HGM or
HGM without CGM. The randomization process is run
separately for the pre-pregnant and pregnant cohorts.
The participant’s random group assignment is determined
via the Centre for Mother, Infant, and Child Research trial
website. They construct a master randomization list using
a permuted block design. The participants are stratified by
mode of insulin therapy (pump vs. MDI) and baseline
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HbA1c (for pregnant group: <7.5 % or 58 mmol/mol vs.
≥7.5 % or 58 mmol/mol; for pre-pregnant group: <8.0 %
or 64 mmol/mol vs. ≥8.0 % or 64 mmol/mol). Within
strata, allocation are assigned in a ratio of 1:1 with random
block sizes.
Intervention
RT-CGM group
Participants randomized to the RT-CGM group are
instructed to use the device on a daily basis. Participants
are taught to insert the sensor device, perform calibra-
tion tests, use insulin dose adjustment algorithms (see
Supplementary Pages for example) and to make changes
to their insulin regimen based on the data from the RT-
CGM and HGM. Additional HGM glucose measurements
may be performed anytime, particularly prior to making
management decisions based on RT-CGM values.
HGM group
Participants randomized to the HGM group are asked to
perform at least 7 finger stick blood glucose measurements
per day. Participants are taught to use insulin dose adjust-
ment algorithms and to make changes to their insulin regi-
men based on data from the HGM.
Follow-up visits and data collection
Visits take place every 4 weeks after randomization. For
the prepregnant cohort, the final visit will be at 24 weeks
following randomization or at the time pregnancy is
confirmed. For the pregnancy cohort, the final visit will
be at 34 weeks gestation. At each visit weight, blood
pressure, insulin type and dose are collected. Glucose
and insulin data are reviewed along with episodes of se-
vere hypoglycemia. Recommendations regarding diabetes
management are made by treating clinicians in routine
antenatal clinics. For the RT-CGM group, the RT-CGM
data are downloaded and the participant’s skin is assessed.
For the HGM groups, a masked CGM is used twice: for
6 days at 12 and 24 weeks in the pre-pregnant cohort and
for 6 days at 24 and 34 weeks gestation in the pregnant
cohort. Data from the masked CGM is downloaded to the
Jaeb Center for independent review. The RT-CGM group
have their RT-CGM data downloaded to the Jaeb Center
for independent review 7–10 days after 12 and 24 weeks
in the pre-pregnant cohort, and 24 and 34 weeks gestation
in the pregnant cohort. Final questionnaires and food diar-
ies for UK participants are repeated at 24 weeks in the
pre-pregnant cohort or at time of conception, and at
34 weeks gestation in the pregnant cohort.
Bloods
Bloods are drawn for HbA1c at randomization, and at 12
and 24 weeks in the pre-pregnant cohort, and at 24 and
34 weeks gestation in the pregnant cohort. Biorepository
bloods are drawn in those that consent, at randomization
and at 34 weeks gestation for the pregnant cohort only.
Delivery
At delivery, cord blood is taken for blood gases (done lo-
cally) and C-peptide. If the participant consents, cord
blood biorepository sample is also collected for future re-
search. Data is collected regarding delivery and neonatal
outcomes. Fetal anthropometrics are done within the first
72 h after delivery. At 6 weeks postpartum data is collected
regarding neonatal wellbeing and maternal satisfaction
with participating in the trial.
Women that are in the pre-pregnant cohort who become
pregnant, continue in the treatment arm they were ran-
domized to, and are followed in a similar fashion to the
pregnant cohort. However, their data are analyzed separ-
ately from the pregnant cohort.
Primary outcome
Pre-pregnant cohort
The primary outcome is glycemic control as measured
by a change in HbA1c from randomization to 24 weeks.
If the participant becomes pregnant before 24 weeks, her
final HbA1c is measured post-confirmation of a positive
pregnancy test.
Pregnant cohort
The primary outcome is glycemic control as measured
by a change in HbA1c from randomization to 34 weeks
gestation. In women who do not progress to 34 weeks
gestation, the latest measured HbA1c is used to contribute
to the primary outcome.
Secondary outcomes
Pre-pregnant cohort
 CGM time in target at baseline, 12 and 24 weeks.
 HbA1c at baseline, 12 and 24 weeks.
Pregnant cohort
 CGM time in target at baseline, 24 and 34 weeks
gestation.
 HbA1c at baseline, 24 and 34 weeks gestation
 Incidence of gestational hypertension/preeclampsia
 Caesarean section: pre-labour and intrapartum
 Gestational weight gain (randomization to
36 weeks)
Pre-pregnant and pregnant cohorts
 Area under the curve (AUC)
a. AUC for CGM glucose > 7.8 mmol/l
b. AUC for CGM glucose > 6.7 mmol/l
Feig et al. BMC Pregnancy and Childbirth  (2016) 16:167 Page 5 of 8
c. AUC for CGM glucose < 3.5 mmol/L
d. AUC for CGM glucose < 2.8 mmol/L
 Hypoglycemia
 Episodes of ‘severe hypoglycemia’ requiring third
party assistance
 Mild-moderate episodes of hypoglycemia from
CGM data <3.5 mmol/L (mild) and <2.8 mmol/L
(moderate) for 20 min duration
 Nocturnal hypoglycemia: CGM glucose
<3.5 mmol/L (mild) and <2.8 mmol/L (moderate)
for 20 min duration between 23.00–07:00 h
 Measures of glucose variability:
 Mean amplitude of glycemic excursions
 SD of CGM measurements
 Mean absolute rate of change of CGM based on
one week of sensor values
 Length of hospital stay associated with delivery
 Questionnaires
 Insulin requirements
 Safety outcome:
A substantial increase in hypoglycemia will be
defined as >10 % increase in hypoglycemic
episodes (<3.5 mmol/L for at least 20 min
duration) over and above the HGM group.
Infant Outcomes.
 Birth weight:
 Infant birth weight >90th centile using national
growth curves
 Infant birth weight >90th centile using
customized centiles
 Infant birth weight <10th centile, using national
growth curves
 Infant birth weight <10th centile using
customized centiles
 Infant birth weight ≥4 kg
 Pregnancy loss: miscarriage, stillbirth, neonatal
death (death ≤28 days of life)
 Preterm birth (<37 weeks and early preterm
<34 weeks)
 Birth injury
 Shoulder dystocia
 Neonatal hypoglycemia
 Hyperbilirubinemia
 Respiratory distress
 High level neonatal care > 24 h
 Cord blood gas pH < 7.0
 Hyperinsulinemia (using cord c-peptide)
 Composite fetal outcome: Pregnancy loss:
miscarriage, stillbirth, neonatal death (death
≤28 days of life), birth injury, neonatal
hypoglycemia, hyperbilirubinemia, respiratory
distress, high level neonatal care > 24 h.
 Sum of skin-folds >90th percentile for gestational age
– triceps, sub scapular, biceps and suprailiac skin-folds
 Anthropometric measures - infant birth weight,
head circumference, chest circumference, abdominal
circumference, left and right upper-arm circumference,
crown-heel length, crown-rump length
 Length of hospital stay until first discharge home
Statistical analysis
Primary Outcome: The primary analysis will compare
the treatment groups on the 24-week HbA1c for the
pre-pregnant cohort and on the 34-week HbA1c for the
pregnant cohort, controlling for baseline HbA1c in an
analysis of covariance that includes the treatment mo-
dality (pump/MDI) and strata used in randomization as
covariates. We will obtain point and interval estimates
of the treatment effect (the mean adjusted difference in
follow-up HbA1c between treated and control groups)
and also test the null hypothesis that the treatment effect
is zero. The primary analysis will follow the intention-to-
treat principle with all participants analyzed in the group
to which they were randomized, regardless of actual sen-
sor wear. In the analysis of the pre-pregnant cohort, in
women who become pregnant before 24 weeks, the final
outcome will be a measurement of HbA1c taken post-
confirmation of pregnancy. In the analysis of the pregnant
cohort, in women who do not reach 34 weeks gestation,
the last HbA1c taken prior to 34-weeks will be used for
the primary outcome. If important covariates remain im-
balanced between treatment groups despite the stratified
randomization, these covariates will be added to the re-
gression model and the difference between adjusted and
unadjusted estimates will be examined to assess the im-
pact of this imbalance. Multiple imputation using earlier
HbA1c measurements will be used to deal with HbA1c
values that are missing at the final assessment.
Sample size estimation
The trial will include 324 participants, with 110 in the
pre-pregnant cohort (women planning pregnancy), and
214 in the pregnant cohort.
In both cohorts, the sample size is based on a clinically
relevant difference in HbA1c of 0.5 %. For pregnant
women, a cross-sectional standard deviation (SD) of 1.1
was used, as it is towards the upper limit of published
HbA1c SD values ([9–11]. In pre-pregnant women, a SD
value of 0.8 was used, based on reported SD values in a
trial of CGM in young adults [12]. As this latter study
also reported the SD of change over 26 weeks, it was
possible to compute the correlation between repeated
measurements. In the various study groups, these cor-
relations ranged from 0.4 to 0.7. To be conservative, we
used the lower value of 0.4 in our sample size calcula-
tions. In both cohorts (pre-pregnant and pregnant),
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sample size was computed for an analysis of covariance
with the final HbA1c as the outcome and baseline
HbA1c and treatment group as predictors. Power was
set at 90 % and the two-tailed significance level was set
at 5 %.
Data management
The continuous glucose monitoring data management
and analyses will be handled by the Jaeb Center for Health
Research, Tampa, Florida. All other data and statistical
aspects will be handled by the Clinical Trials Services/
Centre for Mother, Infant and Child Research, Toronto,
Ontario, and the trial statistician.
Trial steering committee
A trial steering committee will be responsible for the
conduct of the trial. They will meet by teleconference on
a quarterly basis to review the progress of the trial or on
an ad hoc basis should the need arise.
Safety considerations
A Data Safety Monitoring Board (DSMB) will be estab-
lished and will include experts in or representatives of
the fields of endocrinology, obstetrics, epidemiology, and
clinical trials methodology. They will meet after the ini-
tial safety analysis is completed, which will be done after
50 % of the pregnant group has been recruited. Serious
unanticipated adverse events will be reported to the
DSMB should the need arise.
Discussion
Implications of the findings
We aim to evaluate the impact of RT- CGM on glycemic
control in two groups of women, those who are planning
pregnancy and women in early pregnancy. If we find an
improvement, the use of the RT-CGM will be encour-
aged and potentially reimbursed. We may also be able to
determine if RT-CGM is more helpful in certain subsets
of participants (e.g. those using pump or MDI), and
whether the use of RT-CGM will affect maternal and neo-
natal outcomes. If we do not find that RT-CGM is benefi-
cial, then other technologies such as closed-loop insulin
delivery, may be indicated to facilitate optimal glycemic
control in type 1 diabetes pregnancies.
Dissemination
A report will be written for the funding bodies and for
peer-reviewed publication and will be disseminated to
international lay and scientific audiences.
Conclusion
Results from studies in non-pregnant populations sug-
gest that CGM improves glycemic control. Results from
two randomized studies performed during pregnancy are
conflicting, one with and one without improved glycemic
control. This is the first study to look at continuous use of
RT- CGM both in women planning pregnancy and in
women during early pregnancy. It will inform patients,
caregivers, and funding agencies regarding the use of
CGM in the pregnant woman with type 1 diabetes.
Additional file
Additional file 1: Ethics Review Boards That Approved CONCEPTT.
(DOCX 18 kb)
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